Roth says this biopharma stock has room to run on drug momentum, upcoming trial catalysts
- Posted on January 23, 2026
- By CNBC
- 4 Views
Roth says this biopharma stock has room to run on drug momentum, upcoming trial catalysts
Roth's $212 price target implies an additional upside of 32% for shares of Insmed, which have already rallied 160% in the last 12 months.
